Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 8,509 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neoplasm Recurrent Clear all

Conditions: Solid Tumour
Interventions: HLX07, Acetaminophen, dexamethasone, diphenhydramine, 5-HT3 inhibitor; Drug
Lead sponsor: Henlix, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fremont, California

Conditions: Glioblastoma, GBM
Interventions: AZD1775; Biological
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Ovarian Cancer
Interventions: thalidomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Anti-OX40 Agonist Monoclonal Antibody PF-04518600, Avelumab, Azacitidine, Gemtuzumab Ozogamicin, Glasdegib, Glasdegib Maleate, Venetoclax; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVC Major Salivary Gland Carcinoma
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab; Biological · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
Interventions: Ibrutinib, Pembrolizumab, Rituximab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Amivantamab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging; Biological · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 271
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Auburn, California + 229 more

Conditions: Hot Flashes, Prostate Cancer
Interventions: cyproterone acetate, quality-of-life assessment; Drug · Procedure
Lead sponsor: Barr Laboratories; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Pomona, New York

Conditions: Endometrial Cancer
Interventions: BKM120; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions: silicon phthalocyanine 4; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lymphoma
Interventions: filgrastim, rituximab, sargramostim, carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, gemcitabine hydrochloride, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: Doxorubicin hydrochloride, Goserelin acetate, Leuprolide acetate, Zoledronic acid, orchiectomy, strontium chloride Sr; Drug · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 4
States / cities: Orlando, Florida • Wichita, Kansas • Houston, Texas + 1 more

Conditions: Colorectal Cancer
Interventions: cetuximab, ramucirumab, irinotecan hydrochloride; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 255
States / cities: Birmingham, Alabama • Aurora, Colorado • Boulder, Colorado + 182 more

Conditions: Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma, Childhood Soft Tissue Sarcoma, Childhood Supratentorial Primitive Neuroectodermal Tumor, Neuroblastoma, Osteosarcoma, Retinoblastoma, Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: filgrastim; Biological
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 1 Year to 25 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Brain and Central Nervous System Tumors
Interventions: busulfan; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: 8-Chloroadenosine, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Duarte, California

Conditions: Lung Cancer
Interventions: carboplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001
U.S. locations: 57
States / cities: Loma Linda, California • Pomona, California • New London, Connecticut + 46 more

Conditions: Hot Flashes, Prostate Cancer
Interventions: oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill; Dietary Supplement · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 20
States / cities: Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions: DS-1594b, Azacitidine, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Leucovorin, Mesna, Methotrexate, Prednisone, Rituximab, Venetoclax, Vincristine; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostatic Neoplasms, Prostate Cancer
Interventions: Calcitriol, Naproxen-n-butyl nitrate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
Interventions: erlotinib hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: T Cell Lymphoma
Interventions: Sorafenib; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: Enzalutamide, Goserelin acetate, Leuprolide acetate, Radiation therapy; Drug · Radiation
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2040
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: LEE011, BYL719, fulvestrant, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee

Search by objective public record fields.

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer

BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer

Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors

8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer